Trial Profile
Spanish expanded access program of Ipilimumab in patients with malignant melanoma
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 07 Dec 2015
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Expanded access; Therapeutic Use
- 07 Dec 2015 New trial record